Oncology
Bladder Cancer Surgery Just Became a System Test
The FDA has expanded perioperative pembrolizumab plus enfortumab vedotin to all cystectomy-eligible adults with muscle-invasive bladder cancer. The approval is clinical progress. The implementation burden now moves to hospitals.
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
Regulators Start Writing the Rules for AI-Driven Medicines
AI Pathology Moves From Demo to Workflow
FDA Puts AI Inside the Evidence Machine
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Oncology Trials Still Do Not Match the Patients They Will Treat
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.